Canon Medical Offers New Liver Reporting Tool for Ultrasound

December 1, 2020

Canon Medical reminds us that liver disease is one of the major challenges in imaging today, and accurately determining compensated advanced chronic liver disease (cACLD) is extremely important in order to define the right treatment path.

The recently updated guidelines from Society of Radiologists in Ultrasound introduced the “Rule of Four,” a standardized method of using four different levels of shear wave elastography-based liver stiffness to assess the probability of cACLD. To help easily and accurately determine cut off values, Canon Medical Systems USA, Inc.’s premium AplioTM i-series ultrasound platform is now available with software to display the calculated measurement averages from multiple samples of the liver, customizable based on the “Rule of Four.”

The program uses measurements obtained with Shear Wave Elastography, Canon Medical’s technology that provides a quantitative measure and dynamic visual display of tissue stiffness in the liver. In addition, the system provides standard deviation and interquartile range (IQR) data, as well as a simple visual propagation map, to ensure accurate and confident application of the “Rule of Four” to determine cACLD and for the assessment of other liver pathologies.

“The new guidelines from SRU reinforce the importance of quickly and accurately determining cACLD, so that clinicians can chart the right course for patient care,” said Dan Skyba, managing director, Ultrasound Business Unit, Canon Medical Systems USA, Inc. “At Canon Medical, it doesn’t get much easier than automatically calculating that average measurement of tissue stiffness, with our Shear Wave Elastography plus this new liver reporting tool.”

The Aplio i-series will be showcased at this year’s virtual Radiological Society of North America (RSNA), at Canon Medical’s unique, immersive booth experience.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“The completion of the APEX-AV Study represents an important milestone in the catheter-directed therapies CDT space for the treatment of pulmonary embolism. I sincerely thank all the investigators for their commitment and dedication,” said William Brent Keeling, MD, Associate Professor of Surgery, Department of Surgery, at the Emory University School of Medicine, and Immediate Past President, The PERT Consortium™.
The combined expertise of Cordance Medical and the Airan and Williams Labs will see NeuroAccess utilized to deliver a novel application of drug-loaded nanoparticles, providing targeted drug delivery to the brain.
Medixine prepares for 2024 with two key senior hires, VP of Operations in the U.S. and VP of Engineering in Finland. The appointments will enhance support and service to the company’s U.S.-based partners, including leading respiratory homecare provider Lincare and a major medical device manufacturer. In addition, the new hires will enable streamlined design, testing, and deployment of new product features for more patient-centric, cost and time-effective treatment of chronic conditions.
Innovent Biologics and Synaffix: Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates. Synaffix is eligible to receive an upfront payment plus potentialmilestone payments and royalties on commercial sales for each licensed target.
Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.

By using this website you agree to accept Medical Device News Magazine Privacy Policy